Topic

Pharma industry: latest medical news

Deals, earnings, launches and strategy across pharma and biotech.

1. Saturday, October 24, 2026

   Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

   Source: BioPharma Dive

   In a landmark melanoma study, the Moderna/Merck personalized cancer vaccine (intismeran) plus Keytruda cut the risk of relapse or death by 42%, a result that met Wall Street expectations but triggered a 'sell-the-news' share drop.

   Why it mattersThis is a key test of individualized mRNA cancer vaccines in the adjuvant setting; oncologists will want the full ESMO data, and regulators a first look at a new class with its own manufacturing and safety questions.

2. Saturday, October 24, 2026

   Genmab shares rise after Rina-S hits PFS and OS in phase 3 ovarian cancer trial

   Source: RTTNews

   Genmab shares gained about 10% on Friday after the phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer met its primary progression-free survival endpoint and key secondary overall survival endpoint, per RTTNews; Genmab reported a 71% reduction in risk of progression or death and 57% reduction in risk of death versus investigator's-choice chemotherapy.

   Why it mattersPlatinum-resistant ovarian cancer has few effective options, and an OS benefit for an FRα-targeted ADC is a strong regulatory and commercial signal; Genmab plans to discuss the data with regulators. Not investment advice.

3. Saturday, October 24, 2026

   EQT agrees to take diagnostics maker Qiagen private in ~$12.1B deal

   Source: TheBench.Bio

   EQT Private Equity agreed to acquire Qiagen for €46.50 per share in cash, valuing the company at about €10.8 billion ($12.1 billion) including debt; the companies expect the deal to close in mid-2027, subject to shareholder acceptance and regulatory clearances.

   Why it mattersOne of the year's biggest diagnostics and life-science tools take-privates; Qiagen's boards said private ownership could support longer-term investment. Not investment advice.